Cascadian Therapeutics, Inc. (NASDAQ:CASC) insider Scott Dunseth Myers bought 5,500 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was bought at an average price of $3.74 per share, with a total value of $20,570.00. Following the completion of the purchase, the insider now owns 49,716 shares of the company’s stock, valued at $185,937.84. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Cascadian Therapeutics, Inc. (CASC) traded up 1.37% during trading on Monday, reaching $3.69. The company’s stock had a trading volume of 239,823 shares. The stock’s market capitalization is $186.54 million. The company’s 50-day moving average price is $3.92 and its 200 day moving average price is $4.02. Cascadian Therapeutics, Inc. has a 1-year low of $3.18 and a 1-year high of $10.98.

Cascadian Therapeutics (NASDAQ:CASC) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.06. During the same quarter in the prior year, the firm posted ($1.57) earnings per share. Analysts anticipate that Cascadian Therapeutics, Inc. will post $5.02 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/14/cascadian-therapeutics-inc-nasdaqcasc-insider-acquires-20570-00-in-stock.html.

A number of brokerages have commented on CASC. Cantor Fitzgerald restated a “hold” rating and issued a $4.00 target price on shares of Cascadian Therapeutics in a research note on Wednesday, May 10th. Zacks Investment Research downgraded Cascadian Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Cowen and Company restated a “buy” rating on shares of Cascadian Therapeutics in a research note on Wednesday, August 9th. ValuEngine downgraded Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, BTIG Research began coverage on Cascadian Therapeutics in a research note on Friday, April 21st. They issued a “buy” rating for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. Cascadian Therapeutics currently has an average rating of “Hold” and an average target price of $6.17.

A number of hedge funds have recently bought and sold shares of the stock. Perkins Capital Management Inc. boosted its stake in Cascadian Therapeutics by 6.4% in the first quarter. Perkins Capital Management Inc. now owns 48,129 shares of the biopharmaceutical company’s stock worth $199,000 after buying an additional 2,887 shares during the last quarter. OxFORD Asset Management LLP boosted its stake in Cascadian Therapeutics by 11.8% in the second quarter. OxFORD Asset Management LLP now owns 181,323 shares of the biopharmaceutical company’s stock worth $674,000 after buying an additional 19,131 shares during the last quarter. GRT Capital Partners L.L.C. boosted its stake in Cascadian Therapeutics by 50.5% in the second quarter. GRT Capital Partners L.L.C. now owns 58,109 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 19,500 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in Cascadian Therapeutics during the second quarter worth $104,000. Finally, BlueCrest Capital Management Ltd acquired a new stake in Cascadian Therapeutics during the first quarter worth $122,000. 83.86% of the stock is currently owned by institutional investors and hedge funds.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Insider Buying and Selling by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.